November 16, 2016
Bristol-Myers Squibb Company and Enterome, a pioneer in developing pharmaceuticals and diagnostics based on the gut microbiome, announced that they have entered into an Immuno-Oncology focused collaboration agreement for discovering and developing microbiome-derived biomarkers, bioactive molecules, and drug targets. These will be developed as potential companion diagnostics and therapeutics for cancer. Furthermore, through this collaboration, efforts will be made for identifying novel microbiome-derived biomarkers in order to improve clinical outcomes for patients treated with Bristol-Myers Squibb’s Immuno-Oncology portfolio.
Carl Decicco, Ph.D., head of discovery at Bristol-Myers Squibb, said: “We continue to pursue the full potential of Immuno-Oncology by applying rapidly evolving science, technology and research to our strong foundation in harnessing the immune system to fight cancer. Business development has been integral in partnering external innovation with our internal R&D expertise and capabilities. Enterome’s focus on target identification and validation along with their significant experience in microbiome research can help to advance our goal to improve outcomes for patients treated with immunotherapies.”
“We are delighted to collaborate with Bristol-Myers Squibb to help advance the field of Immuno-Oncology. The exciting combination of Bristol-Myers Squibb’s extensive capabilities in Immuno-Oncology with our expertise in identifying novel targets and molecules derived from the gut microbiome is highly complementary, and offers a unique opportunity to develop a new generation of cancer drugs and diagnostics,” said Pierre Belichard, chief executive officer at Enterome.